DK1888103T3 - Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering - Google Patents

Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering

Info

Publication number: DK1888103T3
Authority: DK; Denmark
Prior art keywords: exendin; glp; agonists; delay; prevent
Prior art date: 2005-04-11

Application number

DK06740942.5T

Other languages

English (en)

Inventor

Christen Anderson

Que Liu

Original Assignee

Amylin Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-11

Filing date

2006-04-11

Publication date

2012-04-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36926409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1888103(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-04-11 Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc

2012-04-23 Application granted granted Critical

2012-04-23 Publication of DK1888103T3 publication Critical patent/DK1888103T3/da

Links

238000007634 remodeling Methods 0.000 title abstract 3
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title abstract 2
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title abstract 2
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 2
239000000556 agonist Substances 0.000 title abstract 2
230000000747 cardiac effect Effects 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
206010019280 Heart failures Diseases 0.000 abstract 1
230000003293 cardioprotective effect Effects 0.000 abstract 1
MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Endocrinology (AREA)
Zoology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

DK06740942.5T 2005-04-11 2006-04-11 Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering DK1888103T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US66987605P	2005-04-11	2005-04-11
PCT/US2006/013949 WO2006110887A2 (en)	2005-04-11	2006-04-11	Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling

Publications (1)

Publication Number	Publication Date
DK1888103T3 true DK1888103T3 (da)	2012-04-23

Family

ID=36926409

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK06740942.5T DK1888103T3 (da)	2005-04-11	2006-04-11	Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering

Country Status (5)

Country	Link
US (1)	US8946149B2 (da)
EP (1)	EP1888103B1 (da)
AT (1)	ATE550032T1 (da)
DK (1)	DK1888103T3 (da)
WO (1)	WO2006110887A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2002364586A1 (en)	2001-12-21	2003-07-30	Delta Biotechnology Limited	Albumin fusion proteins
HUE027902T2 (en)	2004-02-09	2016-11-28	Human Genome Sciences Inc Corp Service Company	Albumin fusion proteins
WO2007139941A2 (en)	2006-05-26	2007-12-06	Amylin Pharmaceuticals, Inc.	Composition and methods for treatment of congestive heart failure
PT2373681T (pt)	2008-12-10	2017-04-11	Glaxosmithkline Llc	Composições farmacêuticas de albiglutida
US8691763B2 (en)	2010-05-04	2014-04-08	Glaxosmithkline Llc	Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en)	2012-12-21	2017-11-23	Sanofi	Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
EP3080154B1 (en)	2013-12-13	2018-02-07	Sanofi	Dual glp-1/gip receptor agonists
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080152A1 (en)	2013-12-13	2016-10-19	Sanofi	Non-acylated exendin-4 peptide analogues
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CA3001065A1 (en)	2015-10-14	2017-04-20	Xiaoxi WEI	Compositions and methods for reducing ice crystal formation
JP7221385B2 (ja) *	2018-10-30	2023-02-13	リウ、チアンニン	Ｇｌｐ－１受容体アゴニスト活性を有するｇｌｐ－１ポリペプチドおよびその使用
TW202140058A (zh)	2020-01-30	2021-11-01	美商美國禮來大藥廠	提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4554101A (en)	1981-01-09	1985-11-19	New York Blood Center, Inc.	Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5118666A (en)	1986-05-05	1992-06-02	The General Hospital Corporation	Insulinotropic hormone
ATE164852T1 (de)	1990-01-24	1998-04-15	Douglas I Buckley	Glp-1-analoga verwendbar in der diabetesbehandlung
US5424286A (en)	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US6006753A (en)	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en)	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
ES2293688T5 (es)	1997-08-08	2011-05-04	Amylin Pharmaceuticals, Inc.	Nuevos compuestos análogos de la exendina.
ATE383867T1 (de)	1997-11-14	2008-02-15	Amylin Pharmaceuticals Inc	Neuartige exendin agonisten
MXPA00004670A (es)	1997-11-14	2003-07-14	Amylin Pharmaceuticals Inc	Compuestos agonistas de exendina novedosos.
EP1054594B1 (en)	1998-02-13	2007-07-04	Amylin Pharmaceuticals, Inc.	Inotropic and diuretic effects of exendin and glp-1
US6703359B1 (en)	1998-02-13	2004-03-09	Amylin Pharmaceuticals, Inc.	Inotropic and diuretic effects of exendin and GLP-1
US6284725B1 (en)	1998-10-08	2001-09-04	Bionebraska, Inc.	Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
JP2003532691A (ja)	2000-05-05	2003-11-05	ノボノルディスクアクティーゼルスカブ	重症疾患神経障害
CN103356996A (zh)	2000-05-19	2013-10-23	埃米林药品公司	Glp-1用于制备治疗急性冠脉综合征的药物的用途
NZ519752A (en)	2000-10-20	2005-04-29	Amylin Pharmaceuticals Inc	Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
AU3938402A (en)	2000-12-13	2002-06-24	Lilly Co Eli	Chronic treatment regimen using glucagon-like insulinotropic peptides
AU2002322403A1 (en)	2001-08-23	2003-03-10	Eli Lilly And Company	Glucagon-like peptide-1 analogs
US20030199445A1 (en)	2002-02-07	2003-10-23	Knudsen Lotte Bjerre	Use of GLP-1 compound for treatment of critically ill patients
WO2003084563A1 (en) *	2002-04-04	2003-10-16	Novo Nordisk A/S	Glp-1 agonist and cardiovascular complications
WO2004035762A2 (en)	2002-10-17	2004-04-29	Alkermes Controlled Therapeutics, Inc. Ii	Microencapsulation and sustained release of biologically active polypeptides
US7192922B2 (en)	2002-11-19	2007-03-20	Allegheny-Singer Research Institute	Method of treating left ventricular dysfunction
EP1610811A4 (en)	2002-12-17	2008-03-26	Amylin Pharmaceuticals Inc	PREVENTION AND TREATMENT OF CARDIAC ARRHYTHMIAS
US7186692B2 (en)	2002-12-17	2007-03-06	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7790681B2 (en)	2002-12-17	2010-09-07	Amylin Pharmaceuticals, Inc.	Treatment of cardiac arrhythmias with GLP-1 receptor ligands
EP1631308B1 (en)	2003-05-30	2013-07-31	Amylin Pharmaceuticals, LLC	Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
MXPA05013340A (es)	2003-06-09	2006-03-09	Nastech Pharm Co	Composiciones y metodos para liberacion mucosal incrementada de la hormona del crecimiento.
EP1701731A4 (en)	2003-12-12	2009-08-05	Einstein Coll Med	GLP-1 (9-36) METHOD AND COMPOSITIONS
CA2599594A1 (en)	2004-12-24	2006-07-13	Amylin Pharmaceuticals, Inc.	Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
WO2007139941A2 (en) *	2006-05-26	2007-12-06	Amylin Pharmaceuticals, Inc.	Composition and methods for treatment of congestive heart failure

2006
- 2006-04-11 DK DK06740942.5T patent/DK1888103T3/da active
- 2006-04-11 EP EP06740942A patent/EP1888103B1/en not_active Expired - Lifetime
- 2006-04-11 WO PCT/US2006/013949 patent/WO2006110887A2/en not_active Ceased
- 2006-04-11 US US11/910,730 patent/US8946149B2/en active Active
- 2006-04-11 AT AT06740942T patent/ATE550032T1/de active

Also Published As

Publication number	Publication date
ATE550032T1 (de)	2012-04-15
EP1888103B1 (en)	2012-03-21
US8946149B2 (en)	2015-02-03
EP1888103A2 (en)	2008-02-20
US20090137466A1 (en)	2009-05-28
WO2006110887A3 (en)	2007-03-22
WO2006110887A2 (en)	2006-10-19

Publication	Publication Date	Title
DK1888103T3 (da)	2012-04-23	Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering
SA521431209B1 (ar)	2024-08-05	مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1
JOP20220024A1 (ar)	2023-01-30	مركبات مساعدة لـ gipr
NO331089B1 (no)	2011-10-03	Sammensetning omfattende en GPR119-agonist og en DPP-IV-inhibitor samt fremgangsmate for fremstilling av slike.
DK4209490T3 (da)	2026-02-23	2-(((2,3-dihydrobenzo[b][1,4]dioxan-5-yl)piperidin-1-yl)methyl)-1-((oxetan-2-yl)methyl)-1h-benzo[d]imidazol-6-carboxylsyrederivater og lignende forbindelser som glp-1-modulatorer til behandling af diabetes
NO20084278L (no)	2008-10-30	Bezothiazol derivatives as beta2 adrenoreceptor agonists
WO2008019147A3 (en)	2009-06-11	Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
EA201791281A1 (ru)	2017-11-30	Соединения-коагонисты гип и гпп-1
NZ740644A (en)	2019-10-25	Glucagon receptor agonists
DK1523325T3 (da)	2011-11-21	Fremgangsmåder og sammensætninger til behandling af polycystisk ovariesyndrom
CL2012001298A1 (es)	2012-10-05	Compuestos derivados del acido carbomoil-metilamino acetico sustituido, inhibidores de nep; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de hipertension arterial, hipertension pulmonar, insuficiencia cardiaca, entre otras.
NO20074943L (no)	2007-10-01	Roflumilast for behandlingen av diabetes mellitus
WO2008155900A1 (ja)	2008-12-24	糖鎖付加glp-1ペプチド
EP3765086C0 (en)	2025-01-08	COMPOSITION AFFECTING THE CONCENTRATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) TO ATTENUATE THE EFFECTS OF AGING
NO20072963L (no)	2007-08-03	5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere
EA201391236A1 (ru)	2014-01-30	Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов
EP3922260A3 (en)	2022-06-15	Insulin receptor partial agonists and glp-1 analogues
DK2203430T3 (da)	2011-09-26	N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV)
NO341663B1 (no)	2017-12-18	Cyklopropyl-kondenserte indolobenzaepin HCV NS5B inhibitorer
EA201101187A1 (ru)	2012-10-30	Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
EA201270555A1 (ru)	2012-09-28	Комбинации ингибиторов вируса гепатита с
EA201690660A1 (ru)	2017-03-31	Соединения и способы на основе двойного агониста гип и гпп-1
CY1115633T1 (el)	2017-01-04	Παραγωγα πυραζολο πυριδινης ως αναστολεις της nadph οξειδασης
ATE539748T1 (de)	2012-01-15	Glucokinaseaktivatoren
NO20082497L (no)	2008-06-03	Diarylureaer for behandling av pulmonal hypertensjon